http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022116853-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7582919d328355e879f25bb38f44133b
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-726
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2800-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2800-107
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6849
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6817
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2869
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-07
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
filingDate 2021-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_92b8f05137a461f3a71c1b3e015637a6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2b2ed641ee31f03b3bf32da79b2164a5
publicationDate 2022-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2022116853-A1
titleOfInvention Preparation and use of anti-fshr antibody and antibody-drug conjugate thereof
abstract Provided are the preparation and use of an anti-FSHR antibody and an antibody-drug conjugate thereof. Specifically, provided is an antibody or an antigen-binding fragment thereof, wherein the antibody or the antigen-binding fragment thereof comprises a variable region, which specifically binds to a human follicle-stimulating hormone receptor FSHR, and comprises one, two, three, four, five or six CDRs selected from the following amino acid sequences: SEQ ID NO: 6, 7, 5, 10, 11, and 12. The provided anti-FSHR antibody and the antibody-drug conjugate thereof have broad application prospects in the detection, screening, prevention and treatment of cancers.
priorityDate 2020-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9320199-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110072542-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020033797-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226406542
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID54678599
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399835
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2331
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399834

Total number of triples: 42.